Politics1 min read

STAT+: Pharma critic Bernie Sanders is set to hold major sway over FDA funding bill

By · Via STAT Health · Published by Everything Blog

In short

The pending legislative battle focuses on renewing the Prescription Drug User Fee Act, a mechanism allowing the FDA to collect industry fees to fund medicine reviews. Congress must pass the renewal by Sept. 30 to prevent disruptions to the agency's drug approval operations. With senior Democrats guiding the process, Sanders is uniquely positioned to challenge the core premises of the current regulatory structure.

Key points

  • Failure to renew the user fee legislation threatens to disrupt the agency's drug approval…: Failure to renew the user fee legislation threatens to disrupt the agency's drug approval processes.
  • Senior Democratic lawmakers are set to manage and oversee the legislative drafting proces…: Senior Democratic lawmakers are set to manage and oversee the legislative drafting process.
  • Sanders has historically maintained opposition to the fundamental premise of the user fee…: Sanders has historically maintained opposition to the fundamental premise of the user fee framework.

Sources checked by our analysis pipeline: 1

WASHINGTON – Democrats’ landslide victory in the midterm elections may have significant implications for the upcoming negotiations over a key funding source for the Food and Drug Administration in part by empowering a major critic of the program.

The FDA collects user fees from pharmaceutical companies to fund the agency’s reviews of their medicines. The Prescription User Fee Drug Act must be renewed before the current law expires on Sept. 30. Otherwise, it could disrupt the FDA’s ability to approve medicines.

The power to shape that legislation will fall to senior Democrats, including Sen. Bernie Sanders (I-VT), who is likely to lead the Senate’s health committee. Sanders is one of the few lawmakers who have opposed the core premise of the user fee structure.

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Politics